Have a feature idea you'd love to see implemented?
Let us know!
LYRA Lyra Therapeutics Inc
Price (delayed)
$0.1819
Market cap
$11.91M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.49
Enterprise value
$21.44M
Lyra Therapeutics, Inc. is a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose
Highlights
The debt has declined by 3.9% since the previous quarter
Lyra Therapeutics's net income has shrunk by 58% YoY but it has increased by 3.7% QoQ
The company's revenue fell by 19% QoQ but it rose by 3.4% YoY
LYRA's equity has dropped by 76% year-on-year and by 33% since the previous quarter
LYRA's quick ratio is down by 34% YoY
Key stats
What are the main financial stats of LYRA
Market
Valuations
Earnings
Shares outstanding
65.46M
Market cap
$11.91M
Enterprise value
$21.44M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.58
Price to sales (P/S)
8.09
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
14.57
Revenue
$1.47M
EBIT
-$97.56M
EBITDA
-$97.16M
Free cash flow
-$80.9M
Per share
Balance sheet
Liquidity
EPS
-$1.49
Free cash flow per share
-$1.24
Book value per share
$0.32
Revenue per share
$0.02
TBVPS
$1.2
Total assets
$78.76M
Total liabilities
$58.14M
Debt
$35.32M
Equity
$20.62M
Working capital
$39.49M
Debt to equity
1.71
Current ratio
3.64
Quick ratio
3.59
Net debt/EBITDA
-0.1
Margins
Efficiency
Dividend
EBITDA margin
-6,604.8%
Gross margin
100%
Net margin
-6,635.8%
Operating margin
-6,894.4%
Return on assets
-85.4%
Return on equity
-178.7%
Return on invested capital
-92.8%
Return on capital employed
-152.9%
Return on sales
-6,632.4%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
LYRA stock price
How has the Lyra Therapeutics stock price performed over time
Intraday
2.19%
1 week
1.06%
1 month
-25.45%
1 year
-94.17%
YTD
-96.53%
QTD
-29.22%
Financial performance
How have Lyra Therapeutics's revenue and profit performed over time
Revenue
$1.47M
Gross profit
$1.47M
Operating income
-$101.42M
Net income
-$97.61M
Gross margin
100%
Net margin
-6,635.8%
Lyra Therapeutics's net income has shrunk by 58% YoY but it has increased by 3.7% QoQ
The company's operating income has shrunk by 54% YoY but it rose by 4.1% QoQ
The net margin has dropped by 53% year-on-year and by 19% since the previous quarter
Lyra Therapeutics's operating margin has decreased by 49% YoY and by 19% QoQ
Growth
What is Lyra Therapeutics's growth rate over time
Valuation
What is Lyra Therapeutics stock price valuation
P/E
N/A
P/B
0.58
P/S
8.09
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
14.57
The EPS is up by 6% since the previous quarter but it is down by 4.2% year-on-year
LYRA's equity has dropped by 76% year-on-year and by 33% since the previous quarter
LYRA's price to book (P/B) is 75% less than its last 4 quarters average of 2.3 and 69% less than its 5-year quarterly average of 1.9
The price to sales (P/S) is 92% lower than the last 4 quarters average of 106.5
The company's revenue fell by 19% QoQ but it rose by 3.4% YoY
Efficiency
How efficient is Lyra Therapeutics business performance
The return on equity has dropped by 139% year-on-year and by 24% since the previous quarter
The return on assets has dropped by 56% year-on-year and by 5% since the previous quarter
The ROS has dropped by 53% year-on-year and by 19% since the previous quarter
Dividends
What is LYRA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for LYRA.
Financial health
How did Lyra Therapeutics financials performed over time
The total assets is 35% greater than the total liabilities
Lyra Therapeutics's total liabilities has surged by 60% YoY but it has decreased by 9% QoQ
The total assets has declined by 35% year-on-year and by 17% since the previous quarter
The debt is 71% greater than the equity
LYRA's equity has dropped by 76% year-on-year and by 33% since the previous quarter
The company's debt to equity rose by 44% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.